AstraZeneca rises as key lung cancer drug scores another win

Tagrisso from AstraZeneca has shown positive results in a trial for advanced non-small cell lung cancer patients with a specific genetic mutation. It slowed disease progression and could be the first targeted treatment option for stage 3 patients. AstraZeneca said the trial showed a statistically significant and highly clinically meaningful improvement in progression-free survival for patients whose cancer was unable to be removed by surgery and had responded to initial chemoradiation.